S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
NASDAQ:VXRT

Vaxart Stock Forecast, Price & News

$4.30
-0.23 (-5.08%)
(As of 01/27/2022 04:00 PM ET)
Add
Compare
Today's Range
$4.29
$4.68
50-Day Range
$4.30
$7.96
52-Week Range
$4.10
$24.90
Volume
2.45 million shs
Average Volume
2.89 million shs
Market Capitalization
$539.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.12
30 days | 90 days | 365 days | Advanced Chart
Receive VXRT News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxart and its competitors with MarketBeat's FREE daily newsletter.


Vaxart logo

About Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VXRT
Previous Symbol
NASDAQ:NABI
Employees
28
Year Founded
N/A

Sales & Book Value

Annual Sales
$4.05 million
Book Value
$1.13 per share

Profitability

Net Income
$-32.22 million
Net Margins
-5,414.56%
Pretax Margin
-5,404.17%

Debt

Price-To-Earnings

Miscellaneous

Free Float
121,606,000
Market Cap
$539.63 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/04/2021
Today
1/28/2022
Next Earnings (Estimated)
2/24/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.72 out of 5 stars

Medical Sector

919th out of 1,417 stocks

Biological Products, Except Diagnostic Industry

138th out of 207 stocks

Analyst Opinion: 3.4Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












Vaxart (NASDAQ:VXRT) Frequently Asked Questions

Is Vaxart a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Vaxart stock.
View analyst ratings for Vaxart
or view top-rated stocks.

How has Vaxart's stock price been impacted by COVID-19 (Coronavirus)?

Vaxart's stock was trading at $2.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VXRT stock has increased by 107.7% and is now trading at $4.30.
View which stocks have been most impacted by COVID-19
.

When is Vaxart's next earnings date?

Vaxart is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Vaxart
.

How were Vaxart's earnings last quarter?

Vaxart, Inc. (NASDAQ:VXRT) released its earnings results on Thursday, November, 4th. The biotechnology company reported ($0.14) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.14). The biotechnology company earned $0.20 million during the quarter, compared to analyst estimates of $0.12 million. Vaxart had a negative trailing twelve-month return on equity of 36.10% and a negative net margin of 5,414.56%. The firm's revenue for the quarter was down 24.5% compared to the same quarter last year.
View Vaxart's earnings history
.

When did Vaxart's stock split? How did Vaxart's stock split work?

Shares of Vaxart reverse split before market open on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

What price target have analysts set for VXRT?

4 analysts have issued 12 month price objectives for Vaxart's shares. Their forecasts range from $9.00 to $18.00. On average, they anticipate Vaxart's stock price to reach $13.75 in the next twelve months. This suggests a possible upside of 219.8% from the stock's current price.
View analysts' price targets for Vaxart
or view top-rated stocks among Wall Street analysts.

Who are Vaxart's key executives?

Vaxart's management team includes the following people:
  • Andrei Floroiu, President CEO, CFO & Director
  • Sean N. Tucker, Chief Scientific Officer & Senior Vice President (LinkedIn Profile)
  • Richard Schwartz, Senior Vice President-Technical Operations
  • James F. Cummings, Chief Medical Officer
  • Shaily Jaini Garg, SVP-Clinical Development & Project Management

What other stocks do shareholders of Vaxart own?

What is Vaxart's stock symbol?

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Who are Vaxart's major shareholders?

Vaxart's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Kestra Private Wealth Services LLC (0.04%), AE Wealth Management LLC (0.01%), Fi3 FINANCIAL ADVISORS LLC (0.01%), National Bank of Canada FI (0.00%) and Cutler Group LP (0.00%). Company insiders that own Vaxart stock include Armistice Capital, Llc, Margaret Echerd, Robert A Yedid, Sean Tucker, Todd C Davis and Wouter Latour.
View institutional ownership trends for Vaxart
.

Which major investors are selling Vaxart stock?

VXRT stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP. Company insiders that have sold Vaxart company stock in the last year include Margaret Echerd, Robert A Yedid, Sean Tucker, and Wouter Latour.
View insider buying and selling activity for Vaxart
or view top insider-selling stocks.

Which major investors are buying Vaxart stock?

VXRT stock was purchased by a variety of institutional investors in the last quarter, including Kestra Private Wealth Services LLC, Fi3 FINANCIAL ADVISORS LLC, AE Wealth Management LLC, and National Bank of Canada FI.
View insider buying and selling activity for Vaxart
or or view top insider-buying stocks.

How do I buy shares of Vaxart?

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaxart's stock price today?

One share of VXRT stock can currently be purchased for approximately $4.30.

How much money does Vaxart make?

Vaxart has a market capitalization of $539.63 million and generates $4.05 million in revenue each year. The biotechnology company earns $-32.22 million in net income (profit) each year or ($0.54) on an earnings per share basis.

How many employees does Vaxart have?

Vaxart employs 28 workers across the globe.

What is Vaxart's official website?

The official website for Vaxart is www.vaxart.com.

Where are Vaxart's headquarters?

How can I contact Vaxart?

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at (650) 550-3500, via email at [email protected], or via fax at 650-871-8580.


This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.